University of Mississippi

eGrove

Annual Poster Session 2022

Annual Poster Session

10-11-2022

Does VDAC2 have a BH3 Domain For Binding Bax?

Lillian Ferkany University of Mississippi, laferkan@go.olemiss.edu

Claire Pearson University of Mississippi

Mika B. Jekabsons University of Mississippi

Follow this and additional works at: https://egrove.olemiss.edu/pharm_annual_posters_2022

Recommended Citation

Ferkany, Lillian; Pearson, Claire; and Jekabsons, Mika B., "Does VDAC2 have a BH3 Domain For Binding Bax?" (2022). *Annual Poster Session 2022*. 8. https://egrove.olemiss.edu/pharm_annual_posters_2022/8

This Book is brought to you for free and open access by the Annual Poster Session at eGrove. It has been accepted for inclusion in Annual Poster Session 2022 by an authorized administrator of eGrove. For more information, please contact egrove@olemiss.edu.



Does VDAC2 Have A BH3 Domain For Binding Bax? Lillian Ferkany, Claire Pearson, and Mika B. Jekabsons Department of Biology, , The University of Mississippi, University, MS 38677, USA

Introduction

Mitochondrial outer membrane permeabilization (MOMP) by Bax oligomerization triggers apoptosis. BCL-2 family proteins control apoptosis through their agonist or antagonistic effects on Bax, which is mediated by their conserved BH3 domain. All BH3 domains form an alpha helix containing 5-7 conserved hydrophobic residues and once conserved aspartic acid residue that drive interaction with a canonical hydrophobic groove in Bax and other 'multi-domain' BCl-2 members. BH3 agonists induce Bax oligomerization, whole BH3 antagonists sequester Bax to prevent MOMP. We discovered that voltage dependent anion channels (VDACs) in the MOM contain a putative BH3-like domain. This study aimed to determine if the VDAC2 isoform contains a functional BH3 domain that binds recombinant Bax in a manner similar to the Bim BH3 domain.



Methods

2a. 110 nM rBax or vehicle + cF-labeled fluorescent peptide: 60 mins, 4°C in 0.5% octylglucoside

2b. 10 kDa spin filter, 4°C, to separate free (filtered) from bound peptide

2c. Assess filtrate fluorescence, , $\lambda_{ex} = 494$ nm, $\lambda_{em} = 524$ nm

2d. Bim BH3 domain, alignment with putative VDAC1 BH3 domain, and mutations tested

		H _o		H_1			H ₂		Η	H ₃		H ₄		H₅			
Bim	DLR	ΡE	IR	Ι	ΑQ	Ε	L	R R	Ι	G	DE	F	Ν	ΕT	Y	T R R —	
Bim H ₂ m	DLR	ΡE	ΙR	Ι	ΑQ	E	Α	R R	Ι	G	DE	F	Ν	ΕT	Y	T R R	-
Vdac2S	S	ΙP	ΡP	Y	A D	L	G	ΚA	Α	R	DI	F	N	ΚG	F	G F G L \	/
$Vdac2S H_{0}H_{2}m$	S	ΙP	G P	Y	A D	Α	G	ΚA	Α	R	DI	F	N	ΚG	F	G F G L \	/
Vdac2S H₁H₃m	S	ΙP	ΡΡ	Α	A D	L	G	ΚA	G	R	DI	F	N	ΚG	F	GFGL\	/
$Vdac2S H_2H_4m$	S	ΙP	ΡΡ	Y	A D	Α	G	ΚA	Α	R	DI	G	N	ΚG	F	GFGL\	/
Vdac2S H₃H₅m	S	ΙP	ΡP	Y	A D	L	G	ΚA	G	R	DI	F	N	ΚG	Α	GFGL\	/
Vdac2S Dm	S	ΙP	ΡP	Y	A D	L	G	ΚA	Α	R	RI	F	N	KG	Y	GFGL\	/

Peptide sequences tested are shown in 2d. Data are mean \pm SEM of 5-8 experiments, with each concentration run in triplicate. Equilibrium binding curves were fit to the data assuming one binding site per monomer (black, 19800 fmol), two sites per monomer (red, 39600 fmol), or no constraint (green).

Modeled Results 4.

	ŀ	۲ _d (nM)	B _n	nax (fm	ol)	Hill Number			
	1 Site	2 Sites	No Constraint	1 Site	2 Sites	No Constraint	1 Site	2 Sites	No Constraint	
VDAC2S	-	-	-	_	-	-	-	-	-	
WT	1,048	1,938	1,496	19,800	39,600	32,007	2.06	2.10	3.17	
VDAC2S [H ₀ H ₂] Mutant	1,061	3,824	1,242	19,800	39,600	23,279	1.19	0.93	1.23	
VDAC2S [H ₁ H ₃] Mutant	602	1,552	1,584	19,800	39,600	40,148	1.82	1.38	1.37	
VDAC2S [H ₂ H ₄] Mutant	128	287	326	19,800	39,600	43,643	2.41	1.66	1.59	
VDAC2S [H ₃ H ₅] Mutant	739	2,353	ND	19,800	39,600	ND	1.44	1.08	ND	
VDAC2S [D] Mutant	2,649	7,641	10,090	19,800	39,600	47,895	1.09	0.96	0.94	
Bim	-	-	_	_	_	-	-	-	-	
WT	216	484	3,021	19,800	39,600	204,808	1.96	1.60	1.26	
Bim [H ₂] Mutant	928	1,408	1,101	19,800	39,600	29,561	6.00	2.42	5.46	

3. **Equilibrium Binding With Regression**

